Effect of Valsartan on Carotid Artery Disease

Summary

The EFFERVESCENT trial is designed to evaluate the effects of a specific ARB, called valsartan, on atherosclerosis. The investigators want to know if treatment with valsartan will increase the blood levels of markers responsible for repair of the vessel wall, reduce oxidation and inflammation, improve the function of the blood vessels, and arrest or slow down the progression of atherosclerosis over time.

Timeline

Start

2005-02

Primary completion

2009-11

Completion

2009-11

Drugs

Indications